Lazard Asset Management
ADCT icon

Lazard Asset Management’s ADC Therapeutics ADCT Stock Holding History

Lazard Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-262,595
Closed -$985K – 1940
2026
Q1 		$985K Buy
+262,595
New +$1.04M ﹤0.01% 1172
2025
Q2 		– Sell
-1,203
Closed -$1K – 2279
2025
Q1 		$1K Sell
1,203
-4,615
-79% -$7.84K ﹤0.01% 2220
2024
Q4 		$11K Buy
+5,818
New +$15.2K ﹤0.01% 2100
2022
Q3 		– Sell
-16,098
Closed -$127K – 2283
2022
Q2 		$127K Buy
+16,098
New +$152K ﹤0.01% 1420
2022
Q1 		– Sell
-1,863
Closed -$37K – 2307
2021
Q4 		$37K Buy
+1,863
New +$44.9K ﹤0.01% 1856

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lazard Asset Management's ADCT Position: Q2 2026 in Review

Lazard Asset Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 262,595 shares — an estimated $985K sold.

Lazard Asset Management first reported a position in ADCT in Q4 2021 and held it in 5 quarters. The position peaked at $985K in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Lazard Asset Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 262,595 ADC Therapeutics shares in Q2 2026, an estimated $985K.
  • Lazard Asset Management first reported a position in ADC Therapeutics in Q4 2021 and held it in 5 quarters.
  • Lazard Asset Management's ADC Therapeutics position peaked at $985K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.